Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31...
ADC / XDC
RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that its antibody-drug...
AstraZeneca Sets Sights on $80 Billion Revenue Target and 20 New Molecular Entities by 2030
At its recent investor day, AstraZeneca plc (NASDAQ: AZN), a prominent UK pharmaceutical company, articulated...
Sichuan Biokin’s BL-B01D1 Advances to Phase III for HR+/HER2- Breast Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced the enrollment...
Alphamab Oncology’s JSKN016 Begins Phase I Clinical Trial for Solid Tumor Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company, has announced that the first patient has been...
AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...
Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation
Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...
Mabwell’s 9MW2821 ADC for Triple Negative Breast Cancer Accepted for Review by NMPA
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors
Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...
Zhejiang Huahai Pharmaceutical Wins IND Approval for Antibody-Drug Conjugate from China’s NMPA
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...
Daiichi Sankyo Reports 25.3% Revenue Growth in FY2023, Boosted by Enhertu and Lixiana Sales
Japanese pharmaceutical company Daiichi Sankyo has reported a remarkable fiscal year 2023, with revenues increasing...
Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase...
Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has...
Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform
Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation...
Sichuan Biokin’s BL-B01D1 Earns Breakthrough Designation for Nasopharyngeal Carcinoma Treatment
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...